Ascentage Pharma Group International (HKG:6855)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
45.40
-0.50 (-1.09%)
Apr 3, 2025, 4:08 PM HKT
149.18%
Market Cap 15.56B
Revenue (ttm) 1.04B
Net Income (ttm) -431.45M
Shares Out 342.64M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,986,611
Average Volume 3,668,049
Open 45.10
Previous Close 45.90
Day's Range 43.80 - 46.90
52-Week Range 15.42 - 48.85
Beta 1.05
RSI 66.41
Earnings Date Mar 26, 2025

About HKG:6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 583
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6855
Full Company Profile

Financial Performance

In 2024, HKG:6855's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.

Financial numbers in CNY Financial Statements

News

Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan

JPMorgan initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG), a commercial-stage Chinese biotech company focusing on cancer treatment . In January, Ascentage Pharma’s American depositary shar...

6 days ago - Benzinga

Earnings Scheduled For March 27, 2025

Companies Reporting Before The Bell • Tsakos Energy Navigation (NYSE: TEN) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. • Worksport (NASDAQ: WKSP) is p...

7 days ago - Benzinga

Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025

Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025

8 days ago - GuruFocus

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

2 months ago - Reuters

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American d...

2 months ago - GlobeNewsWire

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO

China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.

2 months ago - Reuters

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China , Dec. 26, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

3 months ago - PRNewsWire

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

4 months ago - PRNewsWire

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

4 months ago - PRNewsWire

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

4 months ago - PRNewsWire

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

ROCKVILLE, Md. and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...

4 months ago - PRNewsWire

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

ROCKVILLE, Md. and SUZHOU, China , Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...

4 months ago - PRNewsWire

ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report

ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to addr...

5 months ago - PRNewsWire

Ascentage Pharma Announces 2024 Interim Results

ROCKVILLE, Md. and SUZHOU, China , Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-cla...

8 months ago - PRNewsWire

Ascentage Pharma Received US$100 Million Option Payment from Takeda

ROCKVILLE, Md. and SUZHOU, China, July 3, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class...

9 months ago - PRNewsWire

Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares

ROCKVILLE, Md. and SUZHOU, China , June 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securi...

10 months ago - PRNewsWire

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda

ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

10 months ago - PRNewsWire

Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR

SUZHOU, China and ROCKVILLE, Md. , June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

10 months ago - PRNewsWire

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma to receive an option payment of 100 mill...

10 months ago - PRNewsWire

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM

SUZHOU, China, and ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

10 months ago - PRNewsWire

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

SUZHOU, China and ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CH...

10 months ago - PRNewsWire

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC

SUZHOU, China, and ROCKVILLE, Md. , June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

10 months ago - PRNewsWire

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB...

11 months ago - PRNewsWire